Trial Profile
Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients With Multivessel Coronary Artery Disease (BEST)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 25 Apr 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions
- Acronyms BEST
- 19 Apr 2022 Results assessing the ability of the 5-year major adverse cardiovascular event (MACE) model to predict treatment benefit of CABG vs PCI in the SYNTAX and BEST trials published in the Journal of the American College of Cardiology.
- 20 Sep 2016 Pooled analysis (n=1166) of individual patient-level data of the SYNTAX and BEST trials published in the Heart.
- 16 Mar 2015 Status changed from active, no longer recruiting to discontinued according to results published in the New England Journal of Medicine.